Taysha Gene Therapies (TSHA) Retained Earnings (2019 - 2026)

Taysha Gene Therapies has reported Retained Earnings for 8 years, with the latest figure at -$753.7 million in Q1 2026.

• Quarterly Retained Earnings fell 20.82% year-over-year to -$753.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$753.7 million (down 20.82% YoY) and the FY2025 annual result came in at -$711.3 million, down 204.93% from the prior year.
• Retained Earnings eased to -$753.7 million in Q1 2026 per TSHA's latest filing, from -$711.3 million in the prior quarter.
• Over five years, Retained Earnings peaked at $677.9 million in Q4 2024 and troughed at -$753.7 million in Q1 2026.
• A 5-year average of -$113.0 million and a median of -$285.8 million in 2022 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2023 and 2025: Retained Earnings soared 247.9% in 2023, then sank 29257.77% in 2025.
• Over 5 years, Retained Earnings stood at $402.4 million in 2022, then surged by 46.11% to $587.9 million in 2023, then grew by 15.29% to $677.9 million in 2024, then slumped by 204.93% to -$711.3 million in 2025, then declined by 5.96% to -$753.7 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$753.7 million, -$711.3 million, and -$683.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.